Announced Fri, 19 Jun · 17:23 IST
Albert David appoints Amit Mahla as Whole-time Director and CEO for 5 years
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹710.50
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.5+0.2-0.7-0.4-1.8+0.9-2.2-3.3——
Up moveDown movePending
AI summary
Board approved Mr. Amit Mahla as Additional Director and Whole-time Director and CEO for 5 years from June 19, 2026 to June 18, 2031. He was already serving as CEO since May 12, 2026. He has 28 plus years of pharma experience across Cipla, Emcure, Glenmark, Alembic, Sun Pharma and JB Pharma. Not related to any director or KMP. Subject to shareholder approval at 87th AGM.
Likely market impact
Formalizes CEO role with 5-year term. Experienced pharma leader from major companies. Positive for governance stability.